Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin
Flozins strike again!
If you missed the biggest NephJC of the year, at least read the highlights here.